Beijing Kawin Technology Share-Holding Co., Ltd. (SHA:688687)
18.70
+0.10 (0.54%)
Sep 23, 2026, 3:00 PM CST
SHA:688687 Revenue
Beijing Kawin Technology Share-Holding had revenue of 269.93M CNY in the quarter ending June 30, 2026, a decrease of -19.39%. This brings the company's revenue in the last twelve months to 1.23B, up 2.58% year-over-year. In the year 2025, Beijing Kawin Technology Share-Holding had annual revenue of 1.32B with 7.35% growth.
Revenue (ttm)
1.23B
Revenue Growth
+2.58%
P/S Ratio
2.54
Revenue / Employee
2.05M
Employees
601
Market Cap
3.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.32B | 90.49M | 7.35% |
| Dec 31, 2024 | 1.23B | -181.71M | -12.87% |
| Dec 31, 2023 | 1.41B | 252.03M | 21.73% |
| Dec 31, 2022 | 1.16B | 15.62M | 1.36% |
| Dec 31, 2021 | 1.14B | 282.30M | 32.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Qingdao Vland Biotech INC. | 1.42B |
| Pulike Biological Engineering | 1.02B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Hubei Goto Biopharm Group | 650.05M |
| Zhejiang Shouxiangu Pharmaceutical | 616.54M |
| Guanhao Biotech | 361.40M |